Cooperative Agreement U43CA302144
Award Date 9/12/25
Completion Date 8/31/26
Dollars Obligated $407K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Washington, DC 20003, USA
Similar Awards
- This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...
- The National Cancer Institute (NCI) awarded a $902,046 Project Grant under the Cancer Detection and Diagnosis Research (CFDA 93.394) federal grant program to Data Driven Bioscience Inc. on January 1, 2025. The grant supports the clinical validation of DuoSeq, a next-generation sequencing (NGS) platform that provides simultaneous DNA and RNA sequencing for the diagnosis of blood cancers. DuoSeq aims to overcome key limitations of existing NGS approaches by streamlining sample preparation,...
- The National Cancer Institute (NCI) has awarded a $554,653 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Institute for Systems Biology (ISB) in Seattle, WA. The 4-year grant titled "RARECYTEFINDER: A BENCH-TO-BITS TOOLKIT FOR LABEL-FREE, WHOLE-SPECTRUM ANALYSIS OF RARE DISSEMINATED TUMOR CELLS IN LIQUID AND TISSUE BIOPSIES" aims to develop an innovative, unbiased method for identifying and analyzing rare disseminated tumor cells (DTCs)...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $399,153 to Alelopharma Inc. to develop an ultra-sensitive molecular diagnostic platform for detecting EML4-ALK gene fusions in non-small cell lung cancer patients. The objective is to create a blood-based "liquid biopsy" test that can accurately identify ALK-positive lesions, which respond well to targeted cancer therapies, without the need for tissue re-biopsy....
- This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $400,000 in funding to Electronic Biosciences, Inc. to develop a novel nanopore-based sequencing approach capable of accurately characterizing repetitive DNA sequences. The project aims to address limitations of current sequencing-by-synthesis methods in accurately sequencing genomic repeats, which are known to harbor variations associated...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $399,998 to Darwin Biosciences, Inc. to develop a low-cost, handheld, and non-invasive lung cancer screening device for use in low-resource settings. The device will incorporate sample collection, nucleic acid biomarker detection via isothermal recombinase polymerase amplification, and a visual readout on lateral flow strips. This work builds on Darwin Biosciences' prior...
- The National Science Foundation (NSF) awarded a $1,250,000 Cooperative Agreement under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Nexgen Cancer Detection LLC. The funding will be used to improve and validate a method for diagnosing cancer earlier through a simple blood draw. The project aims to enrich cancer DNA from blood samples to enable highly sensitive and accurate cancer detection, which could lead to earlier cancer diagnosis and treatment, improved patient...
- The National Cancer Institute (NCI) awarded a $919,366 Project Grant to Nuvox Pharma, L.L.C., a small disadvantaged business located in Tucson, Arizona, under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394). The goal of this 2-year project, running from September 2025 to August 2027, is to evaluate liquid biopsy approaches to differentiate pseudoprogression from true disease progression in glioblastoma (GBM) patients treated with chemoradiation and an oxygen...
- The National Cancer Institute (NCI) awarded Imcare Biotech, Inc. a $364,763 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate SERAVUE AI, a novel multi-analyte algorithmic assay for early detection of hepatocellular carcinoma (HCC), the most common type of primary liver cancer. The project aims to create a highly accurate, non-invasive blood test for HCC surveillance that could potentially replace ultrasound as the standard screening...
- The National Cancer Institute (NCI) awarded a $399,816 Project Grant to Xgenomes Corp., a minority-owned biotechnology company in Cambridge, MA, under the Cancer Detection and Diagnosis Research (CFDA 93.394) federal grant program. The purpose of the 1-year project is to further develop Xgenomes' novel DNA analysis platform that can directly measure both genetic mutations and epigenetic methylation changes with over 100x greater accuracy than current next-generation sequencing methods. The...